US RE49,908 E1
Bispecific binding proteins and uses thereof
Srinath Kasturirangan, Gaithersburg, MD (US); Changshou Gao, Gaithersburg, MD (US); Godfrey Rainey, Gaithersburg, MD (US); Michelle Morrow, Cambridge (GB); Claire Louise Dobson, Cambridge (GB); Stacey Drabic, Gaithersburg, MD (US); Darren Schofield, Cambridge (GB); Gianluca Carlesso, Gaithersburg, MD (US); Kristen Pollizzi, Gaithersburg, MD (US); Yariv Mazor, Gaithersburg, MD (US); Michael Oberst, Gaithersburg, MD (US); Scott A. Hammond, Gaithersburg, MD (US); Brian Lobo, Gaithersburg, MD (US); Prakash Manikwar, Gaithersburg, MD (US); Jonathan Seaman, Cambridge (GB); Simon Dovedi, Cambridge (GB); and Ronald Herbst, Gaithersburg, MD (US)
Assigned to MedImmune, LLC, Gaithersburg, MD (US)
Filed by MedImmune, LLC, Gaithersburg, MD (US)
Filed on Jun. 30, 2021, as Appl. No. 17/364,539.
Application 17/364,539 is a reissue of application No. 15/588,271, filed on May 5, 2017, granted, now 10,457,732, issued on Oct. 29, 2019.
Claims priority of provisional application 62/332,788, filed on May 6, 2016.
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2818 (2013.01) [C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); C07K 16/2878 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/41 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 43 Claims
 
1. A bispecific binding protein that binds to PD-1 and CTLA-4 comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 9, a first light chain comprising the amino acid sequence of SEQ ID NO: 7, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and a second light chain comprising the amino acid sequence of SEQ ID NO: 4.
 
[ 13. A bispecific binding protein that binds to PD-1 and CTLA-4 comprising:
(i) a first heavy chain comprising a VH1-CDR1, VH1-CDR2 and VH1-CDR3, wherein VH1-CDR1 comprises the amino acid sequence of residues 26-35 of SEQ ID NO: 9, wherein VH1-CDR2 comprises the amino acid sequence of residues 50-66 of SEQ ID NO: 9, and wherein VH1-CDR3 comprises the amino acid sequence of residues 99-111 of SEQ ID NO: 9;
(ii) a first light chain comprising a VL1-CDR1, VL1-CDR2, VL1-CDR3, wherein VL1-CDR1 comprises the amino acid sequence of residues 24-41 of SEQ ID NO: 7, wherein VL1-CDR2 comprises the amino acid sequence of residues 55-61 of SEQ ID NO: 7, and wherein VL1-CDR3 comprises the amino acid sequence of residues 94-100 of SEQ ID NO: 7;
(iii) a second heavy chain comprising a VH2-CDR1, VH2-CDR2 and VH2-CDR3, wherein VH2-CDR1 comprises the amino acid sequence of residues 26-35 of SEQ ID NO: 12, wherein VH2-CDR2 comprises the amino acid sequence of residues 50-66 of SEQ ID NO: 12, and wherein VH2-CDR3 comprises the amino acid sequence of residues 99-114 of SEQ ID NO: 12; and
(iv) a second light chain comprising a VL2-CDR1, VL2-CDR2 and VL2-CDR3, wherein VL2-CDR1 comprises the amino acid sequence of residues 24-34 of SEQ ID NO: 4, wherein VL2-CDR2 comprises the amino acid sequence of residues 50-56 of SEQ ID NO: 4, and wherein VL2-CDR3 comprises the amino acid sequence of residues 89-95 of SEQ ID NO: 4.]